EUVIMEDEUVIMED entdecken
Multizentrische Studie

Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis

Aleksander M Bogdanski, Derk C F Klatte, Sobia I Laghari, Alexandra M J Langers, Ananya Das, Barbara A J Bastiaansen, Bert A Bonsing, Evelien Dekker, Jeanin E Van Hooft, Jewel N Samadder, Lodewijk A A Brosens, Lydia G van der Geest und 8 weitere

Familial Cancer · 25.11.2025 · 24 (4)

DOI: 10.1007/s10689-025-00512-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Familial Cancer, online erschienen am 25.11.2025. Verfasst von Aleksander M Bogdanski und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Adenomatous Polyposis Coli, Early Detection of Cancer. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Champions for Hope, Funk-Zitiello Foundation, Joyce E. Baker Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PDAC) surveillance programs are recommended for individuals with a PDAC lifetime-risk ≥ 5% to improve outcomes. While familial adenomatous polyposis (FAP) is linked to increased PDAC risk, robust data to guide surveillance recommendations is lacking. This study evaluates PDAC risk in a large FAP-cohort.Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. The US-cohort (n = 357) and NL-cohort (n = 1000) had a median age at the end of follow-up of 46 years (IQR, 32.0-60.0) and 60 years (IQR, 47.5-72.5), respectively. The cumulative risk of PDAC by age 70 was 1.3% (95% CI, 0.2-8.4) in the US cohort and 0.6% (95% CI 0.2-1.7) in the NL cohort. When combining both FAP-cohorts, the cumulative risk of PDAC by age 70 was 0.7% (95% CI, 0.3-1.8). For comparison, the cumulative incidence of PDAC in the general population at age 70 was 0.3% (95% CI 0.3-0.3), corresponding to a relative risk of 2.2 (95% CI, 0.9-5.7). Our findings indicate that PDAC risk in FAP patients is not statistically significantly higher than in the general population. As the cumulative incidence remains below the 5% threshold, PDAC surveillance is not recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalAdenomatous Polyposis ColiEarly Detection of CancerRisk AssessmentPractice Guidelines as TopicIncidenceAdenomatous Polyposis Coli ProteinNetherlandsUnited StatesRegistriesFollow-Up StudiesRisk FactorsHumansMaleFemaleAdultMiddle AgedAgedAdolescentYoung AdultProspective Studies

Stichwörter der Autor:innen

Familial adenomatous polyposisPancreatic cancerSurveillance

Substanzen

APC protein, humanAdenomatous Polyposis Coli Protein

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Arizona Centers for Digestive Health, Gilbert, AZ, USA.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.

ORCID-Profile: Monique E van Leerdam

Förderung

  • Champions for Hope
  • Funk-Zitiello Foundation
  • Joyce E. Baker Foundation
  • Lynch Polyposis

Zitieren

APA

Bogdanski, A. M., Klatte, D. C. F., Laghari, S. I., Langers, A. M. J., Das, A., Bastiaansen, B. A. J., Bonsing, B. A., Dekker, E., Van Hooft, J. E., Samadder, J. N., Brosens, L. A. A., van der Geest, L. G., Boardman, L., Nielsen, M., van Kouwen, M. C. A., Bisseling, T. M., Wallace, M. B., Riegert-Johnson, D., van Leerdam, M. E., & Dutch Pancreatic Cancer Group (2025). Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Familial Cancer, 24(4). https://doi.org/10.1007/s10689-025-00512-5

Vancouver

Bogdanski AM, Klatte DCF, Laghari SI, Langers AMJ, Das A, Bastiaansen BAJ, et al. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Familial Cancer. 2025;24(4). doi:10.1007/s10689-025-00512-5

BibTeX
@article{Bogdanski2025,
  author = {Bogdanski, Aleksander M and Klatte, Derk C F and Laghari, Sobia I and Langers, Alexandra M J and Das, Ananya and Bastiaansen, Barbara A J and Bonsing, Bert A and Dekker, Evelien and Van Hooft, Jeanin E and Samadder, Jewel N and Brosens, Lodewijk A A and van der Geest, Lydia G and Boardman, Lisa and Nielsen, Maartje and van Kouwen, Mariëtte C A and Bisseling, Tanya M and Wallace, Michael B and Riegert-Johnson, Douglas and van Leerdam, Monique E and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
  title = {Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis},
  journal = {Familial Cancer},
  year = {2025},
  volume = {24},
  number = {4},
  doi = {10.1007/s10689-025-00512-5}
}
Kostenlos starten →